Serge Saxonov - Jun 14, 2023 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov
Stock symbol
TXG
Transactions as of
Jun 14, 2023
Transactions value $
-$116,328
Form type
4
Date filed
6/16/2023, 05:37 PM
Previous filing
May 23, 2023
Next filing
Jul 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Gift $0 -185 -0.02% $0.00 893K Jun 14, 2023 Direct
transaction TXG Class A Common Stock Sale -$42.6K -740 -0.08% $57.50 892K Jun 14, 2023 Direct F1, F2
transaction TXG Class A Common Stock Sale -$70.8K -1.21K -0.14% $58.53 891K Jun 14, 2023 Direct F1, F3
transaction TXG Class A Common Stock Sale -$3.02K -51 -0.01% $59.15 891K Jun 14, 2023 Direct F1, F4
holding TXG Class A Common Stock 27 Jun 14, 2023 See footnote F5
holding TXG Class A Common Stock 870 Jun 14, 2023 See footnote F6
holding TXG Class A Common Stock 183K Jun 14, 2023 See footnote F7
holding TXG Class A Common Stock 16.3K Jun 14, 2023 See footnote F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $57.03 to $58.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $58.05 to $59.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $59.05 to $59.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F6 The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
F7 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F8 The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.